PIK3CA and non-small cell lung carcinoma: Furthermore, selinexor demonstrated antiproliferative activity against a panel of 11 NSCLC cell lines, showing different genetic landscapes: 5 of the 11 NSCLC cell lines had either a K- or N-RAS mutation, 1 of the 11 had loss of PTEN, and 2 of the 11 NSCLC cell lines had PIK3CA mutations.